Cohort for people with chronic myelomonocytic leukemia
Cohort of Patients With Chronic Myelomonocytic Leukemia
This project will collect blood and bone marrow samples from adults with chronic myelomonocytic leukemia at diagnosis and during disease changes to create an anonymized biobank researchers can use to test new questions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris Academic / other |
| Locations | 24 sites (Amiens and 23 other locations) |
| Trial ID | NCT07512882 on ClinicalTrials.gov |
What this trial studies
This is a prospective, non-interventional cohort that collects biological samples and linked anonymized clinical data from adults with CMML. Samples are taken at diagnosis and/or as the disease progresses, with or without treatment, and always alongside routine clinical tests or within other clinical trials. The study accepts patients regardless of disease stage or current treatment, provided they meet monocytosis criteria or have a confirmed CMML diagnosis and give informed consent. Patients with active uncontrolled infections (notably hepatitis B, hepatitis C, or HIV) are excluded to protect safety and sample integrity.
Who should consider this trial
Good fit: Adults (≥18 years) with blood monocytosis ≥0.5 × 10⁹/L and ≥10% of total white blood cells or with a confirmed diagnosis of chronic myelomonocytic leukemia who can give informed consent are ideal candidates.
Not a fit: Patients with active, uncontrolled infections (such as hepatitis B, hepatitis C, or HIV) or those unwilling to consent are not eligible and are unlikely to gain direct benefit from participation.
Why it matters
Potential benefit: If successful, the biobank could help researchers discover biomarkers and biological mechanisms that lead to better CMML diagnostics and targeted treatments.
How similar studies have performed: Biobanks and observational cohorts in myeloid malignancies have previously supported biomarker discoveries and improved disease understanding, but dedicated longitudinal CMML cohorts are less common and this effort helps fill that gap.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years and over * Blood monocytosis ≥ 0.5 × 10⁹/L and ≥ 10% of total white blood cells or * Confirmed diagnosis of chronic myelomonocytic leukemia * Regardless of stage (chronic or transformed), and whether or not currently being treated * Signed informed consent Exclusion Criteria: * Active, uncontrolled infection (particularly hepatitis B, hepatitis C, HIV) * Refusal informed consent
Where this trial is running
Amiens and 23 other locations
- CHU Amiens Picardie — Amiens, France (Not_yet_recruiting)
- CHU Angers — Angers, France (Not_yet_recruiting)
- Hôpital Privé Antony — Antony, France (Not_yet_recruiting)
- AP-HP Hôpital Avicenne — Bobigny, France (Not_yet_recruiting)
- Centre Hospitalier Sud Francilien — Corbeil-Essonnes, France (Not_yet_recruiting)
- CHU Grenoble — Grenoble, France (Not_yet_recruiting)
- AP-HP Hôpital Bicêtre — Le Kremlin-Bicêtre, France (Not_yet_recruiting)
- CHRU Lille Hôpital Claude Huriez — Lille, France (Not_yet_recruiting)
- CHU Limoges — Limoges, France (Not_yet_recruiting)
- CHU Nantes — Nantes, France (Not_yet_recruiting)
- CHU Nice Hôpital l'Archet 1 — Nice, France (Not_yet_recruiting)
- Groupe Hospitalo-Universitaire Caremeau Institut de Cancérologie du Gard — Nîmes, France (Not_yet_recruiting)
- AP-HP Hôpital Saint-Antoine — Paris, France (Not_yet_recruiting)
- AP-HP Hôpital Cochin — Paris, France (Not_yet_recruiting)
- AP-HP Hôpital Necker — Paris, France (Not_yet_recruiting)
- AP-HP Hôpital Saint-Louis — Paris, France (Not_yet_recruiting)
- CHU Bordeaux — Pessac, France (Not_yet_recruiting)
- CHU Poitiers — Poitiers, France (Not_yet_recruiting)
- Centre Henri Becquerel — Rouen, France (Not_yet_recruiting)
- Centre Hospitalier Saint-Brieuc Hôpital Yves Le Foll — Saint-Brieuc, France (Not_yet_recruiting)
- CHU Toulouse — Toulouse, France (Not_yet_recruiting)
- CHU Tours — Tours, France (Not_yet_recruiting)
- CHRU Nancy Brabois — Vandœuvre-lès-Nancy, France (Not_yet_recruiting)
- Gustave Roussy — Villejuif, France (Recruiting)
Study contacts
- Study coordinator: Christophe WILLEKENS
- Email: Christophe.willekens@gustaveroussy.fr
- Phone: +33 1 42 11 23 79
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.